Meta-analyses of good outcomes likelihood ratios for the 4V-remission and 3V-remission status
| Good outcome* | 4V-Remission (vs non-4V) | I2 LR+ LR− | 3V-Remission (vs non-3V) | I2 LR+ LR− | ||
| LR+ (95% CI) | LR− (95% CI) | LR+ (95% CI) | LR− (95% CI) | |||
| ΔmTSS ≤0.5 | 1.36 (1.15 to 1.61) | 0.92 (0.81 to 1.04) | 38% 0% | 1.26 (1.13 to 1.41) | 0.86 (0.79 to 0.94) | 40% 3% |
| ΔmTSS ≤0 | 1.32 (1.17 to 1.50) | 0.91 (0.82 to 1.02) | 19% 0% | 1.20 (1.12 to 1.29) | 0.87 (0.81 to 0.93) | 0% 0% |
| ΔmTSS ≤5 | 1.40 (0.88 to 2.23) | 1.01 (0.76 to 1.33) | 56% 0% | 1.33 (1.03 to 1.71) | 0.92 (0.77 to 1.10) | 40% 0% |
| ΔHAQ-DI ≤0 | 1.34 (1.16 to 1.54) | 0.90 (0.79 to 1.02) | 18% 0% | 1.08 (0.99 to 1.17) | 0.94 (0.88 to 1.02) | 17% 0% |
| ΔHAQ-DI ≤0 and HAQ-DI ≤0.5 | 3.35 (2.78 to 4.03) | 0.60 (0.52 to 0.68) | 72% 45% | 1.82 (1.59 to 2.07) | 0.55 (0.47 to 0.65) | 80% 87% |
4V-remission=SJC28, TJC28, CRP (mg/dL) and PGA (0–10), all ≤1; 3V-remission=SJC28, TJC28 and CRP (mg/dL) ≤1; non-remission=SJC28 >1 or TJC28 >1 or CRP (mg/dL) >1, irrespective of PGA value; at 6 or 12 months of follow-up in all cases.
*n=5792 for ΔmTSS, n=3904 for ΔHAQ-DI ≤0 and n=5262 for ΔHAQ-DI ≤0 and HAQ-DI ≤0.5.
CRP, C reactive protein; ∆HAQ-DI, change in Health Assessment Questionnaire–Disability Index; LR+, positive likelihood ratio; LR−, negative likelihood ratio; ∆mTSS, change in the modified total Sharp score during the second year of follow-up; PGA, patient global assessment; SJC28, swollen 28-joint count; TJC28, tender 28-joint count.